NCT01699828View on ClinicalTrials.gov

Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Smoking CessationTobacco Use Cessation
Interventions
DRUG

Buspirone

The buspirone will be given once as a tablet and encapsulated for blinding.

DRUG

Placebo

Placebo will be lactose and encapsulated for blinding. A single capsule will be given.

Trial Locations (1)

M5S 2S1

Center for Addiction and Mental Health, Toronto

All Listed Sponsors
lead

Centre for Addiction and Mental Health

OTHER

NCT01699828 - Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET | Biotech Hunter | Biotech Hunter